When delivered locally, the RP-182 peptide in the nanocarrier could target macrophages and repolarize M2-type TAMs into M1-type.1094 Specifically, the RP-182 peptide could activate phagocytosis and autophagy in M2 macrophages by activating CD206, restoring these cells to M1-type and further enhancing their abilities to engulf tumor cells and assist with intratumoral CD8+ T cells in tumor antigen recognition.1095 Subsequently, the nanoparticles could introduce ErbB2-targeted CAR into macrophages, programmed to be CAR-macrophages (CAR-M). Here, CD8A is linked to neoplasm.